AACR SPECIAL CONFERENCE IN CANCER RESEARCH

CHEMICALS, MUTATIONS, AND CANCER
Co-Sponsored by the National Cancer Institute of Canada

December 7-12, 1992
Banff Springs Hotel, Banff, Alberta, Canada

CONFERENCE CHAIRPERSON
Lawrence A. Loeb / Seattle, WA

SCIENTIFIC PROGRAM

Keynote Address
Lawrence A. Loeb / Seattle, WA

Lesion Structure
John M. Essigmann / Cambridge, MA
Kenneth Brenlauer / Piscataway, NJ
Paul Hopkins / Seattle, WA
Dinshaw J. Patel / New York, NY

The Biochemistry of Mutagenesis
G. Peter Beardsley / Cambridge, MA
Douglas E. Brash / New Haven, CT
Leonard C. Erickson / Maywood, IL
Arthur P. Grollman / Stony Brook, NY
B. Singer / Berkeley, CA

DNA Damage and Mutations by Oxygen Free Radicals
Robert A. Floyd / Oklahoma City, OK
Max Costa / Tuxedo, NY
Shosuke Kawanishi / Kyoto, Japan
Lawrence J. Marnett / Nashville, TN
Susumu Nishimura / Tsukuba, Japan

Replication and Transcription
Philip C. Hanawalt / Stanford, CA
Harrison Echols / Berkeley, CA
Myron F. Goodman / Los Angeles, CA
Thomas A. Kunkel / Research Triangle Park, NC
Daniel Reines / Atlanta, GA

DNA Repair Diseases
Veronica M. Maher / East Lansing, MI
R. Stephen Lloyd / Nashville, TN
Roger A. Schultz / Baltimore, MD
Christine A. Weber / Livermore, CA
Malcolm C. Paterson / Edmonton, Canada

Endogenous Mutagenesis
Leona D. Samson / Boston, MA
Mark Meuth / Salt Lake City, UT
Jeffrey H. Miller / Los Angeles, CA
Roeland M. Schaaper / Research Triangle Park, NC
Mutsuo Sekiguchi / Fukuoka, Japan

Genomic Instability
Thea D. Tlsty / Chapel Hill, NC
Frederick W. Alt / New York, NY
Curtis C. Harris / Bethesda, MD
Bernard S. Strauss / Chicago, IL
Ted Weinert / Tucson, AZ

Genetic Homeostasis
Robert H. Haynes / Toronto, Canada
Bruce Demple / Boston, MA
Carol A. Gross / Madison, WI
Peter Herrlich / Karlsruhe, Germany
Miroslav Radman / Paris, France

Information and Application Forms
American Association for Cancer Research
Public Ledger Building
620 Chestnut Street, Suite 816
Philadelphia, PA 19106-3483

(215) 440-9300 (215) 440-9313 (FAX)

Application Deadline: October 26, 1992
AACR SPECIAL CONFERENCE IN CANCER RESEARCH

Genetics of Cancer

November 4-8, 1992
Marriott Hilton Head Resort, Hilton Head, South Carolina

Supported by a Generous Grant from
the General Motors Cancer Research Foundation

CONFERENCE CO-CHAIRPERSONS
Webster K. Cavenee / La Jolla, CA
Raymond L. White / Salt Lake City, UT

SCIENTIFIC PROGRAM

Keynote Address
Robert A. Weinberg / Cambridge, MA

Inherited Cancer Genes
Bruce A.J. Ponder / Cambridge, England
Raymond L. White / Salt Lake City, UT
Frank McCormick / Emeryville, CA
Arnold J. Levine / Princeton, NJ
Webster K. Cavenee / La Jolla, CA

Genetic Mechanisms
Carmen Sapienza / La Jolla, CA
Carlo M. Croce / Philadelphia, PA
Neal G. Copeland / Frederick, MD

Molecular Genetics of Mitosis
George F. Vande Woude / Frederick, MD
Carol Greider / Cold Spring Harbor, NY
Andrew Murray / San Francisco, CA
David Beach / Cold Spring Harbor, NY
Erich A. Nigg / Lausanne, Switzerland

Genetic Instability
Geoffrey Wahl / San Diego, CA
C. Thomas Caskey / Houston, TX
Walton Fangman / Seattle, WA

Genetics and Cell Commitment
Stuart A. Aaronson / Bethesda, MD
Mariano Barbacid / Princeton, NJ
M. Geoffrey Rosenfeld / La Jolla, CA
David Anderson / Pasadena, CA
Leo Sachs / Rehovot, Israel

Animal Models
Mario Capecchi / Salt Lake City, UT
Douglas Hanahan / San Francisco, CA
Erwin Wagner / Vienna, Austria

Programmed Cell Death
Stanley J. Korsmeyer / St. Louis, MO
H. Robert Horvitz / Cambridge, MA
John T. Isaacs / Baltimore, MD
Peter Kramer / Heidelberg, Germany

Information and Application Forms
American Association for Cancer Research
Public Ledger Building
620 Chestnut Street, Suite 816
Philadelphia, PA 19106-3483

215-440-9300  215-440-9313 (FAX)
AACR SPECIAL CONFERENCE IN CANCER RESEARCH

Normal and Neoplastic Growth and Development

October 18-22, 1992
Chatham Bars Inn, Chatham (Cape Cod), Massachusetts

CONFERENCE CHAIRPERSON
Arnold J. Levine / Princeton, NJ

PROGRAM COMMITTEE
Edward E. Harlow / Charlestown, MA
Peter M. Howley / Bethesda, MD
David M. Livingston / Boston, MA

SCIENTIFIC PROGRAM

Keynote Address
Robert A. Weinberg / Cambridge, MA

Hematopoiesis I
Irving L. Weissman / Stanford, CA
Charles J. Sherr / Memphis, TN
Alan Bernstein / Toronto, Canada
Elliott D. Kieff / Boston, MA

Hematopoiesis II
Ihor Lemischka / Princeton, NJ
Bruce Mayer / New York, NY
Irvin S. Chen / Los Angeles, CA
Flossie Wong-Staal / La Jolla, CA

Hematopoiesis III
Irwin D. Bernstein / Seattle, WA
Jerry M. Adams / Melbourne, Australia
Joseph B. Bolin / Princeton, NJ
Anton Berns / Amsterdam, The Netherlands

DNA Tumor Viruses
Peter M. Howley / Bethesda, MD
Don Ganem / San Francisco, CA
Joseph R. Nevins / Durham, NC
Sara A. Courtneidge / Heidelberg, Germany

Colon Cancer
Arnold J. Levine / Princeton, NJ
Eric R. Fearon / Baltimore, MD
Steven Powell / Baltimore, MD
Frank McCormick / Emeryville, CA

Myogenesis
Stephen J. Tapscott / Seattle, WA
Peter K. Vogt / Los Angeles, CA
Webster K. Cavenee / La Jolla, CA

Tumor Suppressor Genes
Edward E. Harlow / Charlestown, MA
David M. Livingston / Boston, MA
David E. Housman / Cambridge, MA
Carol L. Prives / New York, NY

Information and Application Forms

American Association for Cancer Research
Public Ledger Building
620 Chestnut Street, Suite 816
Philadelphia, PA 19106-3483
215-440-9300 215-440-9313 (FAX)
The prestigious General Motors Foundation awards for outstanding contributions to cancer research were recently announced for 1992. The Charles F. Kettering Prize for cancer treatment was awarded to Lawrence F. Einhorn, M.D., of Indiana University Medical Center (center); the Charles S. Mott Prize for understanding causes and prevention of cancer to Brian MacMahon, M.D., Ph.D., of the Harvard School of Public Health (upper left), and the Alfred P. Sloan Prize for basic science contributions to cancer research to Christiane Nusslein-Volhard of the Max Planck Institute of Tubingen, Germany (lower right).

Dr. Einhorn is honored for his spectacularly successful use of cisplatin in the treatment of testicular cancer, the most common form of cancer in young men. Once invariably fatal, testicular cancer is now one of the most curable (J. Clin. Oncol., 8: 1777–1781, 1990), and cisplatin is now being used in treating many other cancers. Among Dr. Einhorn’s current projects in germ cell tumors is an attempt to improve results for patients with advanced (poor risk) disease by evaluating a more aggressive five-drug chemotherapeutic regimen. In addition, he is currently evaluating high dose chemotherapy with autologous bone marrow transplantation (double transplant) as initial salvage chemotherapy.

Dr. MacMahon, a distinguished epidemiologist, has devoted a lifetime to the study of hormonal and reproductive factors in breast cancer. He discovered that women having their first child after age 35 are three times more likely to develop breast cancer than women who are first-time mothers before age 20. He and many colleagues have advanced knowledge of the distribution of estrogen fractions in high and low risk populations around the world, showing among other things that cigarette smoking reduces estrogen levels.

Dr. Nusslein-Volhard has identified some 150 genes involved in the embryonic development of fruit flies. Her findings provide a basic blueprint of the development of a single fertilized egg to a complex adult organism. Some of these genes share stretches of DNA with oncogenes, thereby further implicating cancer in embryonic development [see Development (Suppl. 1), pp. 1–10, 1991].

Dr. Einhorn received the B.S. degree from Indiana University in 1965 and his M.D. from the University of Iowa in 1968. He has published over 200 papers. He is board-certified in internal medicine and medical oncology and holds the title of Distinguished Professor of Medicine at the University of Indiana Medical Center. Dr. MacMahon is the Henry Pickering Walcott Professor of Epidemiology, Emeritus, Harvard School of Public Health. His discovery of the significance of the age of first birth in breast cancer development is one of the landmarks of breast cancer research. It is one feature which points to estrogen as a common thread in development of the breast and its malignant disease. It is the concept that has led to the current interest in tamoxifen in breast cancer prevention, now being explored in a massive trial by the National Cancer Institute involving 16,000 high-risk women. Dr. MacMahon was awarded the Prix Lacassagne of the French National League Against Cancer in 1986 and holds honorary doctoral degrees from the University of Athens, Greece, and the State University of New York at Buffalo. Dr. Nusslein-Volhard is a member of the Max Planck Society and Director of the Max Planck Institute for Developmental Biology in Tubingen, where she originally obtained the Ph.D. in genetics. Her achievements have gained wide recognition, including the granting of honorary degrees by Yale, Princeton, and the University of Utrecht.

Sidney Weinhouse